These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 15588342)

  • 1. Persistent HIV type 1 infection in semen and blood compartments in patients after long-term potent antiretroviral therapy.
    Craigo JK; Patterson BK; Paranjpe S; Kulka K; Ding M; Mellors J; Montelaro RC; Gupta P
    AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1196-209. PubMed ID: 15588342
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.
    Saitoh A; Hsia K; Fenton T; Powell CA; Christopherson C; Fletcher CV; Starr SE; Spector SA
    J Infect Dis; 2002 May; 185(10):1409-16. PubMed ID: 11992275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections.
    Nunnari G; Otero M; Dornadula G; Vanella M; Zhang H; Frank I; Pomerantz RJ
    AIDS; 2002 Jan; 16(1):39-45. PubMed ID: 11741161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy.
    Zhang H; Dornadula G; Beumont M; Livornese L; Van Uitert B; Henning K; Pomerantz RJ
    N Engl J Med; 1998 Dec; 339(25):1803-9. PubMed ID: 9854115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy.
    Bacheler L; Jeffrey S; Hanna G; D'Aquila R; Wallace L; Logue K; Cordova B; Hertogs K; Larder B; Buckery R; Baker D; Gallagher K; Scarnati H; Tritch R; Rizzo C
    J Virol; 2001 Jun; 75(11):4999-5008. PubMed ID: 11333879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to efavirenz plus two nucleoside reverse-transcriptase inhibitors in patients with advanced stage human immunodeficiency virus-1 infection in Taiwan.
    Deng SC; Chen MY; Hsieh SM; Sheng WH; Hsiao CF; Hung CC; Chang SC
    J Microbiol Immunol Infect; 2003 Mar; 36(1):10-4. PubMed ID: 12741726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1 DNA levels in peripheral blood mononuclear cells and cannabis use are associated with intermittent HIV shedding in semen of men who have sex with men on successful antiretroviral regimens.
    Ghosn J; Leruez-Ville M; Blanche J; Delobelle A; Beaudoux C; Mascard L; Lecuyer H; Canestri A; Landman R; Zucman D; Ponscarme D; Rami A; Viard JP; Spire B; Rouzioux C; Costagliola D; Suzan-Monti M;
    Clin Infect Dis; 2014 Jun; 58(12):1763-70. PubMed ID: 24647014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV RNA and HIV DNA in peripheral blood mononuclear cells are consistent markers for estimating viral load in patients undergoing long-term potent treatment.
    Burgard M; Izopet J; Dumon B; Tamalet C; Descamps D; Ruffault A; Vabret A; Bargues G; Mouroux M; Pellegrin I; Ivanoff S; Guisthau O; Calvez V; Seigneurin JM; Rouzioux C
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1939-47. PubMed ID: 11153076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor reduction of HIV-1 RNA titres in nucleoside reverse transcriptase inhibitor experienced patients treated with indinavir combination therapy.
    Ball JK; Rowe T; Curran R; Irving WL; Beards GM; Sontag G; Youle M; Moyle G; Pillay D
    Sex Transm Infect; 1999 Oct; 75(5):337-9. PubMed ID: 10616359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of distinct blood lymphocyte populations in human immunodeficiency virus type 1-infected subjects in the absence or presence of effective therapy.
    Derdeyn CA; Kilby JM; Miralles GD; Li LF; Sfakianos G; Saag MS; Hockett RD; Bucy RP
    J Infect Dis; 1999 Dec; 180(6):1851-62. PubMed ID: 10558941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seminal reservoirs during an HIV type 1 eradication trial.
    Nunnari G; Leto D; Sullivan J; Xu Y; Mehlman KE; Kulkosky J; Pomerantz RJ
    AIDS Res Hum Retroviruses; 2005 Sep; 21(9):768-75. PubMed ID: 16218800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy.
    Furtado MR; Callaway DS; Phair JP; Kunstman KJ; Stanton JL; Macken CA; Perelson AS; Wolinsky SM
    N Engl J Med; 1999 May; 340(21):1614-22. PubMed ID: 10341273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men.
    Taylor S; Reynolds H; Sabin CA; Drake SM; White DJ; Back DJ; Pillay D
    AIDS; 2001 Oct; 15(15):2051-3. PubMed ID: 11600838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of drug resistance mutations in plasma and peripheral blood mononuclear cells at different plasma viral loads in patients receiving HAART.
    Chew CB; Potter SJ; Wang B; Wang YM; Shaw CO; Dwyer DE; Saksena NK
    J Clin Virol; 2005 Jul; 33(3):206-16. PubMed ID: 15911442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indinavir/ritonavir 800/100 mg bid and efavirenz 600 mg qd in patients failing treatment with combination nucleoside reverse transcriptase inhibitors: 96-week outcomes of HIV-NAT 009.
    Boyd MA; Siangphoe U; Ruxrungtham K; Duncombe CJ; Stek M; Lange JM; Cooper DA; Phanuphak P
    HIV Med; 2005 Nov; 6(6):410-20. PubMed ID: 16268823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of HIV-1 genotype in plasma RNA and peripheral blood mononuclear cells proviral DNA after interruption and resumption of antiretroviral therapy.
    Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Niubó J; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
    Antivir Ther; 2012; 17(3):577-83. PubMed ID: 22301439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1 viral load in blood and semen plasma of Brazilian patients under antiretroviral therapy.
    Medeiros RP; Munerato P; Diaz RS
    J Clin Virol; 2004 Aug; 30(4):346-7. PubMed ID: 15163426
    [No Abstract]   [Full Text] [Related]  

  • 20. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease.
    Fischl MA; Ribaudo HJ; Collier AC; Erice A; Giuliano M; Dehlinger M; Eron JJ; Saag MS; Hammer SM; Vella S; Morse GD; Feinberg JE; Demeter LM; Eshleman SH;
    J Infect Dis; 2003 Sep; 188(5):625-34. PubMed ID: 12934177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.